{"id":11124,"date":"2026-10-31T04:08:48","date_gmt":"2026-10-31T08:08:48","guid":{"rendered":"https:\/\/www.inflation.us\/news\/?p=11124"},"modified":"2026-10-31T04:08:49","modified_gmt":"2026-10-31T08:08:49","slug":"mark-cubans-cost-plus-drugs-could-be-worth-billions-when-it-goes-public","status":"publish","type":"post","link":"https:\/\/www.inflation.us\/news\/articles\/mark-cubans-cost-plus-drugs-could-be-worth-billions-when-it-goes-public\/","title":{"rendered":"Mark Cuban’s Cost Plus Drugs Could Be Worth Billions When It Goes Public"},"content":{"rendered":"\n
\n\n

\n You may have heard about how Mark Cuban<\/strong> recently left<\/span> Shark Tank<\/strong> to focus on Cost Plus Drugs<\/strong>, a rapidly growing<\/span> healthcare business<\/strong> that is helping Americans<\/strong> access prescription medications at affordable prices<\/span><\/strong>. If Mark Cuban<\/strong> ever decides to take Cost Plus Drugs<\/strong> public, we believe it could potentially achieve a multi-billion-dollar valuation<\/span><\/strong>, making it a major healthcare IPO<\/strong><\/span>.\n <\/p>\n\n

\n One interesting development in the Type 2 diabetes treatment market<\/span><\/strong> is Brenzavvy<\/strong>, an FDA-approved SGLT2 inhibitor<\/strong> positioned as a lower-cost treatment option<\/strong><\/span>. The company’s website identifies two important distribution partners<\/strong>: Mark Cuban’s Cost Plus Drugs<\/strong> and Marley Drug<\/strong>, the growing healthcare business<\/span><\/strong> owned by Medicure (TSXV: MPH)<\/strong>:\n <\/p>\n\n

\n \"Brenzavvy\n <\/p>\n\n

\n Although Mark Cuban’s Cost Plus Drugs<\/strong> advertises a slightly lower listed price<\/strong><\/span> for Brenzavvy<\/strong>, the final cost to customers also depends on shipping charges<\/strong>. Medicure (TSXV: MPH)’s Marley Drug<\/strong> offers free standard shipping<\/strong><\/span>, providing a potentially important competitive advantage<\/span><\/strong>.\n <\/p>\n\n

\n Another important difference is order fulfillment speed<\/span><\/strong>. Marley Drug<\/strong> offers expedited processing and delivery options that may allow eligible orders placed early in the week to arrive within approximately two business days<\/span><\/strong>, depending on the destination and prescription processing requirements. Meanwhile, Cost Plus Drugs<\/strong> has its own processing and shipping timelines. These differences highlight how customer convenience<\/span><\/strong> can become an important competitive factor.\n <\/p>\n\n

\n We believe Mark Cuban’s Cost Plus Drugs<\/strong> is a highly innovative<\/strong><\/span> company with significant long-term potential. However, it remains privately held, while Medicure (TSXV: MPH)<\/strong> is already publicly traded<\/strong><\/span>.\n <\/p>\n\n

\n We believe Medicure (TSXV: MPH)<\/strong> has the potential to become a much more widely recognized healthcare company<\/strong><\/span> as Marley Drug<\/strong> expands. Over the long term, we see substantial upside potential<\/strong><\/span>, although future results and investment returns are uncertain.\n <\/p>\n\n

\n Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA’s President has purchased 87,000 shares of MPH and intends to buy more shares. This message is meant for informational and educational purposes only.<\/em>\n <\/p>\n\n<\/div>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

You may have heard about how Mark Cuban recently left Shark Tank to focus on Cost Plus Drugs, a rapidly growing healthcare business that is helping Americans access prescription medications at affordable prices. If Mark Cuban ever decides to take Cost Plus Drugs public, we believe it could potentially achieve a multi-billion-dollar valuation, making it […]<\/p>\n","protected":false},"author":1,"featured_media":11126,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[365,414,26,8],"class_list":["post-11124","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-biotech","tag-mph","tag-politics","tag-technology"],"_links":{"self":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/comments?post=11124"}],"version-history":[{"count":1,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11124\/revisions"}],"predecessor-version":[{"id":11127,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11124\/revisions\/11127"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media\/11126"}],"wp:attachment":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media?parent=11124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/categories?post=11124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/tags?post=11124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}